Review Maps Mechanisms for Pairing Precision Nutrition With GLP-1 Agonists in Type 2 Diabetes
This narrative review argues that precision nutrition can address non-response and side effects in GLP-1 therapy for obesity and type 2 diabetes by leveraging microbiome, metabolomic, and genetic data. It highlights pharmacoeconomic benefits but rests on mechanistic reasoning without new interventional evidence. Prospective RCTs are needed to confirm clinical and economic gains.
Next steps require multicenter trials measuring primary endpoints of body composition, HbA1c, adherence, and cost per quality-adjusted life year at 52 weeks. Such studies must stratify by baseline microbiome and genetic markers to test the review's core hypothesis that tailored nutrition amplifies GLP-1 efficacy beyond pharmacology alone.
Wilding et al. or similar group: At least one 52-week RCT of precision nutrition plus semaglutide will report a 20% absolute improvement in 12-month adherence versus standard dietary advice by December 2027.
Sources (3)
- [1]Primary Source(https://www.mdpi.com/1424-8247/17/8/1052)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)
- [3]Supporting Source(https://jamanetwork.com/journals/jama/fullarticle/2805759)